



E N T E L O S[®]



For immediate release:

American Diabetes Association Announces Launch of *In Silico* Diabetes Research Center

Entelos Biosimulation Technology to be Made Available to Academic Community

Washington D.C., June 11, 2006 – The American Diabetes Association (ADA) and Entelos, Inc. (LSE: ENTL) announced today during a press briefing at the ADA's 66th Scientific Sessions their plans to establish an *in silico* (computer simulation) research facility to support basic research in type 1 diabetes. This facility, which will initially be located at Entelos' Foster City, CA headquarters, will provide researchers with an unparalleled ability to investigate the onset, progression, and treatment of diabetes.

The diabetes research capabilities at the facility will be made available through the ADA's peer-review grant process. The first research projects will utilize Entelos' Type 1 Diabetes PhysioLab[®] platform, an *in silico* model of the non-obese diabetic (NOD) mouse, the primary animal model used to study type 1 diabetes.

"This initiative is an extension of the successful completion of Entelos' Type 1 Diabetes PhysioLab platform, so it makes sense to start this core facility with projects in Type 1 diabetes," said Richard Kahn, Ph.D., Chief Scientific and Medical Officer, American Diabetes Association. "This novel approach, using biosimulation to complement basic research, has already uncovered numerous insights into the mechanisms and triggers of this disease. These as well as future insights will hopefully accelerate our understanding of human diabetes and lead to successful ways to treat and prevent it."

The Type 1 Diabetes PhysioLab platform was developed over a two-year partnership between Entelos and the ADA. Scientific guidance and oversight was provided by a Scientific Advisory Board comprised of five key scientists and researchers in the area of type 1 diabetes: Mark Atkinson, Ph.D. of University of Florida; Jeffrey Bluestone, Ph.D. of University California San Francisco; George Eisenbarth, M.D., Ph.D. of University Colorado at Denver and Health Science Center; Diane Mathis, Ph.D. of The Joslin Diabetes Center; and Aldo Rossini, M.D. of University of Massachusetts. The platform is currently installed in the laboratories of these researchers' respective academic centers.

"This program holds the promise to help us understand how interactions between multiple immune components affect glucose control and the onset of diabetes in the NOD mouse," said Jeffrey Bluestone, Ph.D., Director, UCSF Diabetes Center and member of the ADA's Scientific Advisory Board. "Research in this platform will enable investigation of critical pathways contributing to and regulating autoimmunity and beta cell destruction, thereby potentially providing insights into approaches to evaluate and halt or reverse disease progression."

Mikhail Gishizky, Ph.D., Chief Scientific Officer for Entelos, added, "With the availability of this technology, academic researchers will for the first time be able to combine the benefits of *in silico* research with their own laboratory investigations. This combination should ultimately improve the rationale for taking novel interventions into humans. We look forward to the contributions that this synergy will make to the field of diabetes."

About Diabetes

Diabetes affects approximately 20.8 million children and adults in the United States and arises in response to the body not producing or properly using insulin. Type 1 diabetes is characterized by the absence or reduced production of insulin due to the autoimmune destruction of islet cells in the pancreas. Type 2 diabetes, which is the most common form of the disease, is characterized by the body's inability to respond to the hormone, although decreased insulin secretion may also occur.

In type 1 diabetes, insulin must be replaced, primarily through daily injections, in order to control plasma glucose. Treatment of type 2 diabetes typically starts with meal planning, weight loss, and exercise. However, medications may also be necessary to control blood glucose levels. Unfortunately, many individuals with diabetes develop significant disease-associated complications, including those of the eye, kidney, and heart. While progress has been made in the ability to identify individuals likely to develop or have the disorder, scientific understanding of the disease is limited by practical considerations in studying humans with the condition.

About the American Diabetes Association

The American Diabetes Association (www.diabetes.org) is the nation's premier voluntary health organization supporting diabetes research, information and advocacy. Founded in 1940, the Association has offices in every region of the country, providing services to hundreds of communities. The Association's commitment to research is reflected through its scientific meetings; education and provider recognition programs; and its Research Foundation and Nationwide Research Program, which fund breakthrough studies looking into the cure, prevention, and treatment of diabetes and its complications. For more information, please visit www.diabetes.org or call 1-800-DIABETES (1-800-342-2383). Information from both these sources is available in English and Spanish.

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company that applies engineering principles and mathematical modeling approaches to simulate human biology. The company helps its pharmaceutical and biotechnology partners increase the efficiency of the drug discovery, development, and commercialization process by accurately predicting human response to therapeutic intervention. Entelos' teams of life scientists and engineers use its proprietary computer platforms, called PhysioLab systems, and create "virtual patients" to test novel therapies, translate animal data to predict human response, and optimize clinical trial designs in diseases such as asthma, obesity, Type I and Type II diabetes, and rheumatoid arthritis. In addition to co-development and internal research programs, Entelos partners with pharmaceutical and biotechnology companies worldwide.

Enquiries

Entelos, Inc.

Jill Fujisaki, Vice President, Investor Relations Tel: +1 650 572 5430 fujisaki@entelos.com

ADA

Diane Tuncer +1.703.549.1500 ext. 5510 dtuncer@diabetes.org

Brunswick Group

Justine McIlroy / Alex Tweed / Jon Coles Tel: +44 207404 5959